Last reviewed · How we verify
EDP-322
At a glance
| Generic name | EDP-322 |
|---|---|
| Sponsor | Enanta Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers (PHASE1)
- Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EDP-322 CI brief — competitive landscape report
- EDP-322 updates RSS · CI watch RSS
- Enanta Pharmaceuticals, Inc portfolio CI